Angiosarcoma

1. Disease Information

Overview

Angiosarcoma is a malignant mesenchymal neoplasm of endothelial cell origin that phenotypically and functionally recapitulates normal endothelium (PMID: 38391320). It is classified among soft tissue sarcomas and represents one of the most aggressive tumor types in this category, characterized by rapid local invasion, high rates of recurrence and metastasis, and poor overall prognosis. The tumor can arise virtually anywhere in the body, with the most common sites being skin (particularly the head and neck region in elderly patients), breast (both primary and radiation-associated), liver, heart, and spleen.

Key Identifiers

Synonyms and Alternative Names

• Hemangiosarcoma
• Malignant hemangioendothelioma
• Malignant angioendothelioma
• Lymphangiosarcoma (when arising from lymphatic endothelium)
• Stewart-Treves syndrome (when arising in the setting of chronic lymphedema post-mastectomy)

Information Sources

The information in this report is derived from aggregated disease-level resources including the SEER database, published case series, prospective clinical trials, genomic profiling studies, and systematic reviews. Individual patient-level data are referenced where available from clinical trials and case reports.

2. Etiology

Disease Causal Factors

Angiosarcoma arises through multiple distinct etiological pathways:

Sporadic/Primary: The majority of angiosarcomas arise spontaneously without identifiable environmental exposure. These tumors are driven by somatic mutations in angiogenic signaling pathways, particularly KDR (VEGFR2) mutations found in 70% of primary mammary angiosarcomas, PIK3CA/PIK3R1 mutations (70%), and PTPRB mutations (30%) (PMID: 32123305). The KDR p.T771R hotspot mutation was identified in 6 of 10 tumors with evidence suggestive of biallelism, indicating strong selection for enhanced VEGFR2 signaling.

Radiation-Associated: Secondary angiosarcomas arise in previously irradiated fields, most commonly after breast-conserving therapy for breast carcinoma. The median latency from index radiotherapy is 9.1 years (range 3.7–46.3 years) (PMID: 38791996). These tumors are molecularly defined by near-universal MYC amplification (100% of cases) and frequent FLT4 coamplification (25%) (PMID: 20949568). The incidence of secondary breast angiosarcoma increased 3-fold from approximately 10 to 30 cases per 100,000 person-years between 1992 and 2016 (P = 0.0037) (PMID: 37725702).

Chemically-Induced: Hepatic angiosarcoma has well-established associations with environmental carcinogens. A landmark US survey (1964–1974) identified 168 cases of hepatic angiosarcoma, of which 25% were associated with known etiologic factors including vinyl chloride monomer exposure, thorotrast (thorium dioxide) use in angiography, inorganic arsenic exposure, and androgenic-anabolic steroid treatment (PMID: 7199426). Vinyl chloride exposure was first recognized as a cause of hepatic angiosarcoma in the mid-1970s among polymerization workers (PMID: 945708). More recently, aristolochic acid exposure has been implicated in Asian liver angiosarcoma cohorts, with 80% (8/10) of liver angiosarcoma cases displaying a significant SBS22 mutation signature (PMID: 41394772).

UV-Associated: Head and neck angiosarcomas in sun-exposed skin carry UV mutational signatures (SBS7), with UV-positive cases harboring significantly higher tumor mutational burden than UV-negative cases (P = 0.0294) (PMID: 37106027).

Chronic Lymphedema-Associated (Stewart-Treves Syndrome): Angiosarcoma arising in the setting of chronic lymphedema following mastectomy and axillary lymph node dissection, first described by Stewart and Treves in 1948 (PMID: 26617830).

Risk Factors

Genetic Risk Factors

• TP53 germline variants (Li-Fraumeni syndrome): Germline TP53 pathogenic variants predispose to angiosarcoma, particularly in the context of prior radiotherapy. A novel germline TP53 variant (c.788del) was identified in a patient who developed radiation-associated angiosarcoma (PMID: 39734593). A novel germline risk allele in CHEK2 (p.P35L) was also identified in a Li-Fraumeni-like family with cardiac angiosarcoma (PMID: 36387164).
• Xeroderma pigmentosum: Patients with XP have elevated skin cancer risk including angiosarcoma, due to defective nucleotide excision repair (PMID: 39221877).

Environmental Risk Factors

Demographic Risk Factors

• Age: Median age at diagnosis is 69 years (range 0–102) (PMID: 35478727)
• Sex: Male predominance overall; male:female ratio approximately 3:1 for hepatic AS
• Race/Ethnicity: Predominantly non-Hispanic Caucasian (75.4% in SEER data)

Protective Factors

No well-established genetic or environmental protective factors have been identified for angiosarcoma. Avoidance of known carcinogens (vinyl chloride, arsenic, excessive UV) reduces risk for specific subtypes. Female sex has been identified as a positive prognostic factor for hepatic angiosarcoma (HR 0.68, 95% CI 0.536–0.875, P < 0.05) (PMID: 39676119).

Gene-Environment Interactions

The interaction between germline TP53 variants and ionizing radiation represents the best-characterized gene-environment interaction in angiosarcoma. Patients with Li-Fraumeni syndrome who receive radiotherapy have significantly elevated risk of developing secondary angiosarcoma, as radiation-induced DNA damage overwhelms already-compromised DNA damage response pathways. Similarly, xeroderma pigmentosum patients exposed to UV radiation develop cutaneous angiosarcoma at increased rates due to defective nucleotide excision repair.

3. Phenotypes

Clinical Presentations by Site

Cutaneous Angiosarcoma (Head and Neck)

• Phenotype type: Physical manifestation — raised, violaceous or erythematous plaques/nodules on sun-exposed skin
• HPO terms: HP:0100242 (Sarcoma), HP:0000951 (Abnormality of the skin)
• Age of onset: Typically elderly (median ~70 years)
• Severity: Severe — aggressive local invasion with multifocal disease
• Progression: Rapidly progressive
• Frequency: Most common subtype of cutaneous angiosarcoma
• QoL impact: Severe — disfiguring facial lesions cause significant psychological distress

Breast Angiosarcoma

• Phenotype type: Physical manifestation — mass or skin changes in breast
• HPO terms: HP:0100242 (Sarcoma), HP:0100013 (Neoplasm of the breast)
• Onset: Primary: median age 31 years; Radiation-associated: median age 68–72 years; latency 4–12 years post-RT (PMID: 19433291)
• Severity: Variable — graded by Rosen's method (low, intermediate, high)
• Frequency: 0.1–0.2% of malignant breast neoplasms

Cardiac Angiosarcoma

• Phenotype type: Clinical signs — pericardial effusion, cardiac tamponade, dyspnea
• HPO terms: HP:0001698 (Pericardial effusion), HP:0002094 (Dyspnea)
• Location: Predominantly right atrium
• Severity: Severe — most aggressive primary cardiac malignancy
• Clinical features: Hemorrhagic pericardial effusion, cardiac tamponade (PMID: 41320327)

Hepatic Angiosarcoma

• Phenotype type: Clinical signs — abdominal pain, hepatomegaly, hepatic rupture
• HPO terms: HP:0001392 (Abnormality of the liver), HP:0002027 (Abdominal pain)
• Severity: Extremely poor prognosis — 3-year survival rate 6.7% (PMID: 39676119)

Splenic Angiosarcoma

• Phenotype type: Clinical signs — acute abdominal pain, splenic rupture, hemoperitoneum
• HPO terms: HP:0001743 (Abnormality of the spleen), HP:0002027 (Abdominal pain)
• Severity: Nearly universally fatal — most patients die within 12 months

Pulmonary Metastatic Disease

• Phenotype type: Symptoms — hemoptysis (73% of patients), dyspnea
• HPO terms: HP:0002105 (Hemoptysis), HP:0002094 (Dyspnea)
• Imaging: Bilateral, randomly distributed, variably shaped nodules with ground-glass opacities
• Common misdiagnoses: Tuberculosis (45%), vasculitis (18%) (PMID: 28885371)

Laboratory Abnormalities

• Anemia (from hemorrhage or microangiopathic hemolytic process)
• Thrombocytopenia (consumptive coagulopathy / Kasabach-Merritt phenomenon)
• Elevated LDH

4. Genetic/Molecular Information

Somatic Driver Genes and Pathogenic Variants

Primary/Sporadic Angiosarcoma

Source: PMID: 32123305 — "Recurrent genomic alterations were identified in KDR (70%), PIK3CA/PIK3R1 (70%), and PTPRB (30%), each at higher frequencies than reported in AS across all sites. Six tumors harbored a KDR p.T771R hotspot mutation, and all seven KDR-mutant cases showed evidence suggestive of biallelism."

Head and Neck (UV-Associated) Angiosarcoma

UV-positive cases had significantly higher TMB than UV-negative cases (P = 0.0294) (PMID: 37106027).

Radiation-Associated Angiosarcoma

Source: PMID: 20949568 — "High-level MYC amplification was found in 100% of secondary AS, but in none of the AVL or other radiation-associated sarcomas. Coamplification of FLT4 (encoding VEGFR3) was identified in 25% of secondary AS."

PMID: 25863565 — "Amplification (5- to 20-fold) of the c-myc oncogene was found in all breast radiation-induced angiosarcomas (32 tumours) but in none of the 15 primary angiosarcomas except one (7%). This study reinforces that there are true pathogenetic differences between the two types of breast angiosarcomas."

Hepatic Angiosarcoma

• K-ras-2 point mutations found in 29% of tumors (7/24), including both sporadic (26%) and Thorotrast-induced (40%) cases. Mutations were characteristic of oxidative damage (G:C > A:T and G:C > T:A) (PMID: 9010458).
• Aristolochic acid signature (SBS22) identified in 80% of Asian liver angiosarcoma cases (PMID: 41394772).

Epigenetic Information

• Radiation-associated angiosarcomas show a distinct transcriptome signature featuring upregulation of lymphatic endothelial markers (PDPN, PROX-1, VEGFR3, EDNRA), suggesting origin from radiation-stimulated lymphatic endothelial cells (PMID: 22532251).
• MYC amplification drives upregulation of the miR-17-92 cluster with concomitant downregulation of thrombospondin-1 (THBS1), linking MYC to angiogenic promotion (PMID: 22383169).
• Alternative lengthening of telomeres (ALT) activation has been identified as a hallmark of liver angiosarcoma (PMID: 41394772).

Chromosomal Abnormalities

• MYC amplification at 8q24.21 (5- to 20-fold) — hallmark of radiation-associated AS
• CDKN2A/CDKN2B losses at 9p21.3 — more frequent in radiation-associated (71%) than sporadic (39%) sarcomas (P = 6.92e-3) (PMID: 31243333)
• Gains of 17q24.2-17qter identified in subsets of post-radiation angiosarcomas
• Rare ALK rearrangements reported in epithelioid angiosarcoma (PMID: 41836264)

5. Environmental Information

Environmental Factors

• CHEBI terms: Vinyl chloride (CHEBI:28509), Arsenic (CHEBI:22632), Aristolochic acid (CHEBI:22574)

Lifestyle Factors

No specific lifestyle factors (smoking, diet, exercise, alcohol) have been definitively linked to angiosarcoma risk beyond the occupational and environmental exposures listed above. Androgenic-anabolic steroid use has been associated with hepatic angiosarcoma in rare cases (PMID: 7199426).

Infectious Agents

Viral hepatitis (HBV, HCV) has been investigated but not confirmed as a major risk factor for hepatic angiosarcoma. In a Taiwanese study, 2 of 9 patients had hepatitis C infection and none had hepatitis B, with no evidence supporting a major viral role (PMID: 22200164).

6. Mechanism / Pathophysiology

Molecular Pathways

Angiosarcoma pathogenesis involves convergent activation of several key signaling cascades:

VEGF/VEGFR Signaling (Primary Pathway) - KDR (VEGFR2) activating mutations drive autocrine/paracrine VEGF signaling - FLT4 (VEGFR3) amplification in radiation-associated AS enhances lymphangiogenic signaling - VEGF stimulates tumor proliferation via VEGFR2 phosphorylation (PMID: 23522954)

PI3K-AKT-mTOR Pathway - PIK3CA activating mutations (H1047R hotspot) found in both human AS and canine HSA - mTOR/S6K activation demonstrated in vascular tumors including angiosarcoma; rapamycin inhibits growth (PMID: 23938603) - Combined MEK + mTOR inhibition shows synergistic anti-tumor effects in AS tumorgrafts (PMID: 25955301)

RAS-MAPK Pathway - NRAS activating mutations (G61R) in 24% of canine HSA - K-ras-2 mutations in hepatic AS (29%), characteristic of oxidative damage - MEK inhibitor sensitivity demonstrated in AS tumorgraft models

MYC Signaling (Radiation-Associated) - MYC amplification → upregulation of miR-17-92 cluster → suppression of THBS1 → enhanced angiogenesis (PMID: 22383169) - MYC also drives cell cycle progression and metabolic reprogramming

Wnt/β-Catenin Pathway - SFRP2 overexpression activates calcineurin/NFATc3 pathway and β-catenin signaling - Anti-SFRP2 monoclonal antibody reduced angiosarcoma tumor volume by 58% (P = 0.004) (PMID: 23604067)

Tie2/Angiopoietin Pathway - Tie2 universally expressed in human angiosarcomas - Tie2 antagonism combined with VEGFR inhibition shows synergistic anti-tumor effects (PMID: 22431921)

Causal Chain: From Trigger to Clinical Manifestation

Environmental trigger (radiation/UV/chemical)
    OR
Sporadic somatic mutations
│
▼
Endothelial cell DNA damage / Oncogenic activation
(MYC amplification | KDR/PIK3CA mutations | K-ras mutations)
│
▼
Constitutive activation of:
  - VEGF/VEGFR signaling → proliferation
  - PI3K/AKT/mTOR → survival, metabolism
  - RAS/MAPK → growth, differentiation
  - MYC → cell cycle, angiogenesis (via miR-17-92/THBS1)
│
▼
Loss of cell cycle control (CDKN2A/p53 loss)
│
▼
Uncontrolled endothelial proliferation
Aberrant vascular channel formation
│
▼
Local invasion, hemorrhage, distant metastasis

Cellular Processes

• Angiogenesis (GO:0001525) — central to tumor biology; tumor cells form dysfunctional vascular channels
• Cell proliferation (GO:0008283) — driven by VEGFR, PI3K, and MAPK signaling
• Apoptosis resistance (GO:0006915) — ROCK knockdown enhances survival through reduced caspase cleavage (PMID: 22934846)
• Cell migration (GO:0016477) — essential for invasion and metastasis
• Inflammation — gene expression profiling identifies inflammation as a distinguishing feature (PMID: 21062482)

Cell Types Involved

• Vascular endothelial cells (CL:0000071) — cell of origin
• Lymphatic endothelial cells (CL:0002138) — particularly in radiation-associated AS
• Tumor-infiltrating T cells (CL:0000084) — CD3+, CD4+, CD8+ cells correlate with immunotherapy response
• Tumor-associated macrophages — contribute to immunosuppressive microenvironment

Immune System Involvement

The tumor microenvironment of angiosarcoma is characterized by: - Variable immune infiltration — higher TIL density correlates with better immunotherapy response - PD-L1 expression in 32% of post-radiation breast AS specimens (PMID: 41693531) - Upregulation of immune checkpoints (CTLA4, LAG3, PD-1, CD86) in tumor-infiltrating immune cells (PMID: 40575034) - CXCL12-CXCR4 axis as a crucial mediator of the TME (PMID: 40474296) - Lower immune infiltrate at tumor periphery associated with more aggressive behavior (PMID: 31243333)

Single-Cell and Spatial Transcriptomics Findings

Single-cell RNA sequencing of breast angiosarcoma revealed significant differences in perivascular cells, fibroblasts, T cells, endothelial cells, and myeloid cells compared to invasive breast cancer. Key genes FAT4, KDR, FN1, and KIT were highly expressed in angiosarcoma endothelial cells, correlating with poor prognosis (PMID: 40474296).

Spatial transcriptomics of head and neck angiosarcoma revealed topological immune landscapes with distinct spatial organization of immune cell populations (PMID: 37106027).

Single-cell transcriptomic analysis of pancreatic angiosarcoma liver metastasis demonstrated marked upregulation of NF-κB, HIF-1, and MYC signaling, with an immunosuppressive and angiogenic tumor ecosystem (PMID: 40575034).

7. Anatomical Structures Affected

Organ Level

Primary Sites:

Common Metastatic Sites: - Lung (most common) — UBERON:0002048 - Liver — UBERON:0002107 - Bone — UBERON:0001474 - Lymph nodes — UBERON:0000029 - Brain — UBERON:0000955

Tissue and Cell Level

• Vascular endothelium (UBERON:0001986) — tissue of origin
• Lymphatic endothelium — particularly in radiation-associated subtypes
• Cell populations: Endothelial cells (CL:0000071), pericytes (CL:0000669)

Subcellular Level

• Cell membrane (GO:0005886) — VEGFR2, Tie2 receptor signaling
• Nucleus (GO:0005634) — MYC transcription factor activity, TP53 function
• Cytoplasm (GO:0005737) — PI3K/AKT/mTOR signaling cascade

8. Temporal Development

Onset

• Primary angiosarcoma: Typically adult-onset, median age 69 years; primary breast AS median age 31 years
• Radiation-associated AS: Median latency 9.1 years (range 3.7–46.3) from index radiation
• Chemically-induced hepatic AS: Latency 20–40+ years from exposure onset
• Onset pattern: Insidious — often misdiagnosed due to nonspecific presentation

Progression

Staging: The AJCC staging system for soft tissue sarcomas applies. At presentation, tumors are frequently high grade (Grade III 17.2%, Grade IV 19%, unknown 50.6%) but half are considered localized (PMID: 35478727).

Progression Rate: Rapidly progressive — median PFS 7 months, median OS 20 months across all subtypes (PMID: 40500777).

Disease Course: Aggressive, progressive course with high rates of local recurrence and distant metastasis. 12 of 36 patients (33%) developed local recurrence and 12 developed metastasis in one head/neck AS series (PMID: 38391320).

Critical Periods

Early diagnosis and complete surgical resection represent the critical window for optimal outcomes. Once metastatic disease develops, prognosis is uniformly poor. The median OS for patients with pulmonary metastases was only 5.0 months (PMID: 28885371).

9. Inheritance and Population

Epidemiology

• Incidence: Age-adjusted incidence rate approximately 1.4 per million per year (PMID: 35478727)
• Prevalence: Extremely rare — <1–2% of all soft tissue sarcomas
• SEER data: 5,135 patients identified between 1975 and 2016

Inheritance Patterns

Angiosarcoma is predominantly a sporadic cancer without Mendelian inheritance. However: - Li-Fraumeni syndrome (autosomal dominant TP53 mutations) — increased risk, especially with radiation exposure - Xeroderma pigmentosum (autosomal recessive) — increased risk of UV-associated AS - Familial cases: Rare; a CHEK2 p.P35L variant was identified in a family with cardiac angiosarcoma (PMID: 36387164)

Population Demographics

• Sex ratio: Overall slight male predominance (46% male in SEER); hepatic AS has strong male predominance (~3:1); breast AS almost exclusively female
• Race/Ethnicity: Non-Hispanic Caucasian 75.4%; Non-Hispanic Asians/Pacific Islanders overrepresented in hepatic AS (17%) (PMID: 39676119)
• Age distribution: Predominantly elderly; median age 69 years overall; younger for primary breast AS (median 31)
• Geographic variation: Higher liver AS incidence in Asia (aristolochic acid exposure); historically elevated in industrial areas with vinyl chloride exposure

10. Diagnostics

Histopathology and Immunohistochemistry

Histological diagnosis relies on identification of malignant endothelial cells forming abnormal vascular channels. Morphologic spectrum ranges from well-differentiated vasoformative patterns to poorly differentiated solid sheets of epithelioid or spindle cells.

Essential IHC Panel:

MYC IHC: c-MYC immunostain is consistently positive in radiation-associated AS and negative/weakly positive in primary AS — serves as a diagnostic marker for distinguishing these subtypes (PMID: 34392127, PMID: 24457083).

MYC FISH: Confirms MYC amplification with 100% concordance with protein expression in mammary AS (PMID: 24457083).

Imaging Studies

• MRI: Preferred for soft tissue characterization; hemorrhagic, heterogeneously enhancing masses
• CT: Assessment of extent and metastatic disease
• PET-CT: Useful for staging and response assessment
• Cardiac MRI: Superior to echocardiography for detecting cardiac masses (PMID: 28885371)

Molecular/Genetic Testing

• Targeted NGS panels: Identify actionable mutations in KDR, PIK3CA, TP53, NRAS
• MYC FISH: Diagnostic for radiation-associated vs primary AS
• TMB assessment: Predictive of immunotherapy response in UV/radiation-associated subtypes
• Whole-exome sequencing: For comprehensive genomic profiling and germline testing

Differential Diagnosis

11. Outcome/Prognosis

Survival and Mortality

Prognostic Factors

Negative prognostic factors (multivariate): - Age > 70 years (HR 1.67, P < 0.05) - No surgical intervention (HR 2.29, P < 0.001) - Distant stage (HR 2.54, P < 0.001) - Angiosarcoma histology (HR 2.95 for local relapse in superficial sarcomas, P < 0.001) (PMID: 40961809) - Higher tumor grade - Larger tumor size - Non-cutaneous location

Positive prognostic factors: - Female sex (HR 0.68 for hepatic AS) - Localized disease - Complete surgical resection with R0 margins - Younger age

Complications

• Hemorrhage (tumor rupture, especially splenic and hepatic)
• Disseminated intravascular coagulation
• Cardiac tamponade (cardiac AS)
• Treatment-related thrombotic microangiopathy (PMID: 41177756)

12. Treatment

Surgical Treatment

Wide surgical excision is the mainstay of treatment for localized angiosarcoma. In SEER data, 66.1% of patients underwent surgery (PMID: 35478727). Complete resection with negative margins (R0) is critical — patients without R0 margins had significantly worse outcomes (HR 2.60 for LRFS, P < 0.001; HR 2.02 for OS, P < 0.001) (PMID: 40961809).

• MAXO terms: MAXO:0000004 (surgical procedure), MAXO:0000015 (mastectomy)

Chemotherapy

First-line agents: - Paclitaxel — anti-angiogenic and cytotoxic; widely used for cutaneous AS - Doxorubicin/liposomal doxorubicin — standard for soft tissue sarcomas - Gemcitabine ± docetaxel — alternative regimen

Neoadjuvant chemotherapy: Applied to improve R0 resection rates; response evenly divided between poor (Grades I–II) and good responders (Grades III–IV) (PMID: 38722225).

• MAXO terms: MAXO:0000058 (chemotherapy)

Immunotherapy

Immune checkpoint inhibitors represent an emerging treatment paradigm, particularly for UV- and radiation-associated subtypes:

Cemiplimab (anti-PD-1): Phase II CEMangio trial in secondary AS — ORR 27.8% (4 PR, 1 CR), median PFS 3.7 months, median OS 13.1 months. High intratumoral CD3+ (P = 0.019), CD4 (P = 0.046), and CD8+ density associated with response (PMID: 40632032).

Cabozantinib + nivolumab: Alliance A091902 second-line — ORR 59%, demonstrating significant efficacy in both cutaneous and non-cutaneous AS (PMID: 40056281).

Dual ICI (SWOG S1609): ORR 25% — suggests potential benefit but limited activity in cutaneous disease (PMID: 40056281).

Pembrolizumab: Sustained response reported in PD-L1-expressing angiosarcoma; one patient achieved marked liver disease shrinkage with no new lesions for 8+ months off therapy (PMID: 28716069).

• MAXO terms: MAXO:0001360 (immune checkpoint inhibitor therapy)

Targeted Therapy

• Anti-VEGF/VEGFR agents: Bevacizumab, pazopanib, sorafenib, sunitinib — variable efficacy; sunitinib showed limited activity against AS in preclinical models (PMID: 23522954)
• mTOR inhibitors: Rapamycin shows synergy with MEK inhibitors in AS (PMID: 25955301)
• Anti-SFRP2 antibody: Reduced AS tumorgraft volume by 58% (P = 0.004) (PMID: 23604067)
• CDK4/6 inhibitors: Suggested by frequent cell cycle dysregulation (PMID: 41246336)
• Anlotinib, lenvatinib: Multi-kinase inhibitors used in refractory disease

Radiation Therapy

Adjuvant radiation therapy is used for local control, particularly for head/neck cutaneous AS. However, radiation is used cautiously for radiation-associated subtypes.

• MAXO terms: MAXO:0000014 (radiation therapy)

Experimental Treatments

• Photodynamic therapy (PDT): Promising for recurrent superficial cutaneous AS (PMID: 40364848)
• IFN-alpha: Inhibited angiosarcoma growth in murine models by 71–79% through angiogenesis inhibition (PMID: 16689662)
• Anti-extracellular vimentin vaccine (iBoost): In canine HSA, median OS increased from 136 to 235 days when combined with doxorubicin (PMID: 41009669)
• Toripalimab + gemcitabine/nab-paclitaxel: Achieved 9-month partial response in radiation-associated laryngeal AS (PMID: 41496010)

13. Prevention

Primary Prevention

• Occupational safety: Elimination of vinyl chloride exposure through engineering controls and regulatory limits — largely achieved in developed countries
• Arsenic exposure reduction: Clean water initiatives in endemic areas
• UV protection: Sun-protective measures for head/neck AS prevention
• Judicious use of radiotherapy: Appropriate patient selection and field design

Secondary Prevention

• Surveillance after breast radiation: Clinical monitoring for skin changes in irradiated fields, given 3-fold increased incidence of secondary breast AS. Hemangiosarcoma SIR was 27.11 (95% CI 21.6–33.61) on breast/trunk skin after breast radiation (PMID: 38457179)
• Monitoring chronic lymphedema patients: Regular examination for Stewart-Treves syndrome
• Germline TP53 testing: In patients with early-onset or radiation-associated AS, to identify Li-Fraumeni syndrome for cancer surveillance in families

Tertiary Prevention

• Close surveillance for local recurrence and metastatic disease after treatment
• Multidisciplinary follow-up with sarcoma specialists
• Prompt treatment of recurrences

14. Other Species / Natural Disease

Canine Hemangiosarcoma

Canine hemangiosarcoma (HSA) is the most important comparative model for human angiosarcoma. It is a common spontaneous malignancy in dogs, particularly in golden retrievers, German shepherds, and Labrador retrievers.

Taxonomy: Canis lupus familiaris (NCBI Taxon: 9615)

Genomic Similarities: Whole-exome sequencing of 47 golden retriever HSAs revealed striking parallels with human angiosarcoma: - PIK3CA mutations: 46% (vs. 70% in human primary mammary AS) - TP53 mutations: 66% - NRAS mutations: 24% (G61R hotspot) - PLCG1 mutations: 4% - PTEN mutations: 6%

"Overall, we identified potential driver mutations in over 90% of the cases, including well-documented (in human cancers) oncogenic mutations in PIK3CA (46%), PTEN (6%), PLCG1(4%), and TP53 (66%), as well as previously undetected recurrent activating mutations in NRAS (24%)" (PMID: 32210430).

"Canine tumors share mutational hotspots with human tumors in oncogenes including PIK3CA, KRAS, NRAS, BRAF, KIT and EGFR. Hotspot mutations with significant association to tumor type include NRAS G61R and PIK3CA H1047R in hemangiosarcoma" (PMID: 37414794).

Clinical Features: Splenic HSA is the most common form, characterized by rapid growth, splenic rupture, and hemoperitoneum. Median survival after splenectomy alone is 1–3 months; with adjuvant doxorubicin, 5–7 months (PMID: 41009669). Stage III disease and hepatic metastases are associated with significantly decreased survival (P < 0.001) (PMID: 41742582).

Gene expression profiling identified inflammation and angiogenesis as distinguishing features of canine HSA compared to non-malignant endothelial cells (PMID: 21062482).

Other Species

Angiosarcoma/hemangiosarcoma is recognized in multiple mammalian species but is particularly prevalent in dogs. The shared mutational landscape and biological behavior make canine HSA an invaluable One Health model for drug development.

15. Model Organisms

In Vivo Models

Canine Hemangiosarcoma (Spontaneous) - Model type: Large animal, spontaneous - Phenotype recapitulation: Excellent — shared driver mutations, aggressive behavior, vascular origin, metastatic patterns - Applications: Drug development, immunotherapy testing, biomarker discovery - Limitations: Heterogeneous genetic background; breed-specific predispositions may not fully reflect human disease - Key cell isolates: Used for tumorgraft models and in vitro drug screening

Murine Models - SVR cell line: Transformed murine endothelial cells expressing oncogenic H-ras; forms angiosarcomas in nude mice (PMID: 16689662) - MS1-VEGF cell line: Murine endothelial cells expressing VEGF; low-grade angiosarcoma model - HAMON xenograft: Human angiosarcoma cell line xenograft in immunodeficient mice; expresses CD31, VEGFR2 (PMID: 23522954) - Applications: Drug testing (MEK/mTOR inhibitors, anti-angiogenic agents, immunotherapy)

In Vitro Models

• Human angiosarcoma cell lines (limited availability)
• Canine HSA cell isolates — used for drug combination studies
• Patient-derived xenografts (PDX) / tumorgrafts

Model Limitations

• Murine xenograft models lack intact immune system
• Cell line models may not capture tumor heterogeneity
• Canine HSA, while closely related, is not identical to human AS (e.g., MYC amplification is not a feature of canine HSA)
• Limited availability of human AS cell lines due to disease rarity

Key Findings — Detailed Evidence

Finding 1: Angiosarcoma is a Rare, Aggressive Vascular Malignancy with Poor Prognosis

Analysis of 5,135 patients in the SEER database (1975–2016) demonstrated an age-adjusted incidence rate of approximately 1.4 per million, with the majority of patients presenting as non-Hispanic Caucasian (75.4%) with a median age of 69 years. Tumor grades were predominantly high at presentation (Grade III 17.2%, Grade IV 19%), and the overall 5-year survival was 26.7% (95% CI 25.4–28.1%). A single-institution cohort of 128 patients confirmed poor outcomes with median PFS of 7 months and median OS of 20 months. Importantly, non-cutaneous angiosarcoma had significantly worse median OS than cutaneous disease (9 vs 36 months, P = 0.04), highlighting the prognostic importance of anatomic site.

Finding 2: MYC Amplification Defines Radiation-Associated Angiosarcoma

MYC amplification at 8q24 (5- to 20-fold) is present in 100% of radiation-associated breast angiosarcomas but in only 0–7% of primary angiosarcomas, establishing it as both a diagnostic biomarker and a mechanistic driver. FLT4 (VEGFR3) coamplification occurs in 25% of secondary AS. Downstream, MYC amplification drives upregulation of the miR-17-92 cluster and suppression of the anti-angiogenic factor thrombospondin-1, providing a mechanistic link between MYC and the angiogenic phenotype.

Finding 3: Primary Angiosarcoma Has Distinct Angiogenic Driver Mutations

Primary mammary angiosarcomas harbor recurrent activating mutations in KDR (70%), PIK3CA/PIK3R1 (70%), and PTPRB (30%), all at higher frequencies than in angiosarcoma across all sites. The KDR T771R hotspot mutation shows evidence of biallelism, indicating strong selection for constitutive VEGFR2 activation. Head/neck UV-associated angiosarcomas have a distinct mutational profile dominated by CSMD3, LRP1B, MUC16, POT1, and TP53 mutations with high TMB.

Finding 4: Canine Hemangiosarcoma as a Comparative Model

Canine hemangiosarcoma shares driver mutations in PIK3CA (46%), TP53 (66%), and NRAS (24%) with human angiosarcoma, with identical hotspot mutations (PIK3CA H1047R, NRAS G61R). This genomic convergence, combined with similar clinical behavior, validates canine HSA as a One Health model for therapeutic development.

Finding 5: Immunotherapy Shows Emerging Activity

Immune checkpoint inhibitors demonstrate meaningful activity in angiosarcoma, particularly in UV- and radiation-associated subtypes. The CEMangio phase II trial showed an ORR of 27.8% with cemiplimab in secondary AS, with high intratumoral CD3+ and CD8+ density predicting response. The cabozantinib-nivolumab combination achieved a remarkable 59% ORR in second-line, suggesting synergy between anti-angiogenic and immune checkpoint blockade.

Finding 6: Environmental Carcinogens Cause Distinct Subtypes

Vinyl chloride, thorotrast, arsenic, ionizing radiation, and UV radiation each cause distinct angiosarcoma subtypes through different mutagenic mechanisms — from oxidative DNA damage (K-ras mutations in hepatic AS) to DNA adduct formation (aristolochic acid SBS22 signature) to direct chromosomal amplification events (MYC in radiation-associated AS).

Mechanistic Model: Integrated Pathogenesis of Angiosarcoma Subtypes

┌─────────────────────────────────────────────────────────────────┐
│                    ANGIOSARCOMA SUBTYPES                        │
├─────────────┬──────────────┬────────────┬──────────┬────────────┤
│  Primary/   │  Radiation-  │ UV-Head/   │ Chemical │ Lymphedema │
│  Sporadic   │  Associated  │   Neck     │ Hepatic  │ (Stewart-  │
│             │              │            │          │  Treves)   │
├─────────────┼──────────────┼────────────┼──────────┼────────────┤
│ KDR (70%)   │ MYC amp      │ UV sig     │ K-ras    │ Unknown    │
│ PIK3CA(70%) │ (100%)       │ (SBS7)     │ (29%)    │ drivers    │
│ PTPRB (30%) │ FLT4 (25%)   │ High TMB   │ SBS22    │            │
│             │ CDKN2A loss  │ CSMD3,POT1 │ (AA)     │            │
├─────────────┼──────────────┼────────────┼──────────┼────────────┤
│             │              │            │          │            │
│   VEGFR2 ←──→  MYC/miR ←──→  DNA       │  Oxid.  │ Chronic    │
│   PI3K/AKT  │  17-92      │  repair    │  damage  │ inflam.    │
│   mTOR      │  THBS1↓     │  defects   │          │            │
├─────────────┴──────────────┴────────────┴──────────┴────────────┤
│            CONVERGENT DOWNSTREAM PATHWAYS                       │
│  ┌─────────────────────────────────────────────────────┐       │
│  │ Angiogenesis ↑ │ Cell cycle ↑ │ Apoptosis ↓        │       │
│  │ VEGF/VEGFR    │ CDKN2A loss  │ TP53 loss           │       │
│  │ Tie2/Ang      │ MYC          │ PI3K/AKT            │       │
│  └─────────────────────────────────────────────────────┘       │
│                          ↓                                      │
│           Malignant Endothelial Proliferation                   │
│           Aberrant Vascular Channel Formation                   │
│           Local Invasion → Hemorrhage → Metastasis              │
└─────────────────────────────────────────────────────────────────┘

Evidence Base

Landmark Papers

Limitations and Knowledge Gaps

1. Rarity precludes large randomized trials: Most treatment evidence comes from retrospective series, small phase II trials, and case reports. No phase III randomized trials exist for any angiosarcoma treatment.

2. Molecular heterogeneity: The marked molecular diversity across subtypes makes unified treatment approaches challenging. Better subtype-specific trial designs are needed.

3. Limited understanding of primary sporadic AS pathogenesis: While radiation-associated and chemical subtypes have clear initiating events, the triggers for primary sporadic AS remain largely unknown.

4. Biomarker validation: Predictive biomarkers for immunotherapy response (TMB, PD-L1, TIL density) require prospective validation in larger cohorts.

5. Incomplete genomic landscape: Whole-genome sequencing has been performed on limited cohorts; non-coding mutations, structural variants, and epigenomic alterations remain underexplored.

6. Lack of standardized staging: The AJCC staging system for soft tissue sarcomas may not adequately capture the prognostic nuances of angiosarcoma across different anatomic sites.

7. Limited cell line resources: Few authenticated human angiosarcoma cell lines exist, hampering preclinical drug development.

8. Underrepresentation of non-Western populations: Most genomic and clinical data derive from Western populations; the role of aristolochic acid in Asian liver AS is only now being characterized.

Proposed Follow-up Experiments/Actions

1. Prospective biomarker-stratified clinical trials: Design trials stratifying patients by molecular subtype (MYC-amplified, KDR-mutant, high-TMB) to match targeted therapies to specific driver alterations.

2. Combinatorial immunotherapy-TKI trials: Given the 59% ORR with cabozantinib-nivolumab, expand this approach with additional anti-angiogenic/ICI combinations across subtypes.

3. Comprehensive genomic profiling: Perform whole-genome sequencing on a large, multi-institutional angiosarcoma cohort to identify non-coding drivers, structural variants, and novel therapeutic targets.

4. Canine comparative trials: Leverage canine HSA as a platform for rapid therapeutic testing — particularly for PIK3CA inhibitors, NRAS-targeted approaches, and immunotherapy combinations.

5. Single-cell multi-omics: Expand scRNA-seq studies to characterize the tumor microenvironment across subtypes, with focus on identifying determinants of immunotherapy response.

6. Liquid biopsy development: Develop ctDNA assays for MYC amplification, KDR mutations, and other actionable alterations to enable non-invasive diagnosis and monitoring.

7. CDK4/6 inhibitor trials: Given frequent CDKN2A loss across subtypes, test CDK4/6 inhibitors (palbociclib, ribociclib) as single agents and in combinations.

8. MEK + mTOR combination trials: Translate preclinical synergy data into clinical trials for patients with RAS/MAPK pathway-activated angiosarcomas.

9. Epidemiological surveillance: Monitor aristolochic acid-associated liver angiosarcoma in Asian populations and implement public health interventions.

10. Patient-partnered research: Expand the Angiosarcoma Project (ASCProject) to increase patient enrollment, diversity, and longitudinal follow-up for this rare disease.

Report generated: 2026-05-05 Sources: SEER database analyses, genomic profiling studies, clinical trials, systematic reviews, and comparative oncology studies spanning 93 reviewed publications.